Ventyx Biosciences (VTYX) Competitors

Ventyx Biosciences (NASDAQ:VTYX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Do institutionals & insiders have more ownership in VTYX or AVIR?

97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 18.2% of Ventyx Biosciences shares are held by company insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has preferable valuation and earnings, VTYX or AVIR?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ventyx Biosciences	N/A	N/A	-$192.96M	-$1.98	-0.57
Atea Pharmaceuticals	N/A	N/A	-$135.96M	-$2.00	-1.42

Do analysts rate VTYX or AVIR?

Ventyx Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 792.86%. Atea Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 112.01%. Given Ventyx Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Ventyx Biosciences is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ventyx Biosciences	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Atea Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media favor VTYX or AVIR?

In the previous week, Atea Pharmaceuticals had 7 more articles in the media than Ventyx Biosciences. MarketBeat recorded 8 mentions for Atea Pharmaceuticals and 1 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 1.87 beat Atea Pharmaceuticals' score of 0.16 indicating that Ventyx Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Ventyx Biosciences	Very Positive
Atea Pharmaceuticals	Neutral

Does the MarketBeat Community believe in VTYX or AVIR?

Ventyx Biosciences received 12 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. However, 47.50% of users gave Atea Pharmaceuticals an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote.

Company	Underperform	Outperform
Ventyx Biosciences	Outperform Votes 31 46.97%	Underperform Votes 35 53.03%
Atea Pharmaceuticals	Outperform Votes 19 47.50%	Underperform Votes 21 52.50%

Is VTYX or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -34.90% beat Ventyx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ventyx Biosciences	N/A	-54.94%	-50.01%
Atea Pharmaceuticals	N/A	-34.90%	-32.38%

Which has more volatility and risk, VTYX or AVIR?

Ventyx Biosciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

Summary

Ventyx Biosciences beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.